https://www.clinicaltrialsarena.com/news/intelgenx-alzheimers-disease-trial/
IntelGenx reports data from Phase IIa Alzheimer's disease trial
Jul 4, 2024 - IntelGenx has announced results from its Phase IIa trial of Montelukast (MTK) in adults with mild to moderate Alzheimer's disease (AD).
data fromreportsphaseiiaalzheimer
https://news.dailymushroom.co/intelgenx-announces-intention-to-issue-shares-in-payment-of-principal-and-interest-on-outstanding-debentures/
IntelGenx Announces Intention to Issue Shares in Payment of Principal and Interest on Outstanding...